Invega Sustenna Injection 150 mg contains Paliperidone Palmitate, a long-acting atypical antipsychotic developed for the treatment and maintenance of schizophrenia and schizoaffective disorder in adults. Paliperidone, the active metabolite of risperidone, works by balancing the activity of dopamine and serotonin in the brain. This dual receptor modulation helps control psychotic symptoms, stabilize mood, and improve cognition and behavior in patients with chronic psychotic disorders.

The prefilled syringe formulation of Invega Sustenna delivers a long-acting monthly injection, providing sustained therapeutic drug levels. This reduces the need for daily oral medication, enhances adherence, lowers relapse risk, and simplifies long-term management. The 150 mg dosage is particularly used as an initial or adjustment dose, allowing rapid attainment of effective plasma concentrations, which is crucial during the initiation of therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Invega Sustenna Injection 150 mg is indicated for:

• Acute and maintenance treatment of schizophrenia in adults

• Management of schizoaffective disorder, as part of a comprehensive treatment plan

• Prevention of relapse in patients previously stabilized on paliperidone or risperidone therapy

This long-acting injectable formulation is ideal for patients with adherence challenges or for those requiring sustained symptom control and relapse prevention.

Dosage and Administration

• Initiation regimen: The first dose is typically 150 mg on Day 1 administered intramuscularly in the deltoid muscle, followed by 100 mg on Day 8

• Maintenance dose: After the initial two doses, monthly injections are administered according to clinical response; maintenance doses commonly range from 75–150 mg

• The injection can be administered in either the deltoid or gluteal muscle

• Dose adjustments may be necessary depending on patient response, tolerability, and renal function

• Invega Sustenna should be administered by a trained healthcare professional using proper intramuscular injection techniques

Patients should be monitored for therapeutic efficacy, adverse reactions, and extrapyramidal symptoms throughout therapy.

Precautions and Warnings

• Use with caution in patients with cardiovascular disease, history of arrhythmias, or prolonged QT interval

• Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension

• Metabolic changes, such as weight gain, hyperglycemia, and dyslipidemia, may occur; regular monitoring is recommended

• Not approved for use in elderly patients with dementia-related psychosis due to increased risk of mortality

• Avoid abrupt discontinuation to prevent relapse of psychotic symptoms

• Monitor renal function in patients with kidney impairment, as paliperidone is primarily excreted renally

Patients should report symptoms such as severe dizziness, fainting, involuntary movements, or allergic reactions promptly.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Invega Sustenna Injection 150 mg is generally well tolerated. Common side effects include:

• Pain, redness, or swelling at the injection site

• Dizziness or sedation

• Weight gain or metabolic changes

• Extrapyramidal symptoms, including tremor or rigidity

• Elevated prolactin levels, potentially causing menstrual irregularities, breast enlargement, or sexual dysfunction

Rare but serious side effects may include neuroleptic malignant syndrome, severe cardiovascular events, or serious allergic reactions.

Storage

Store below 30°C in a dry place, protected from light. Do not freeze. Keep the prefilled syringe in its original packaging until use and out of reach of children.

Invega Sustenna Injection 150 mg (Paliperidone Palmitate) is a safe, effective, and convenient long-acting antipsychotic option for achieving rapid and sustained symptom control, preventing relapse, and supporting treatment adherence in patients with schizophrenia and schizoaffective disorder.